Kevad Bio

Argobio, GeneCode and University of Helsinki partner to develop a new class of small molecule activating the GFRa1/RET complex for the treatment of Parkinson's disease and other indications


  • Scientific founder : Prof. Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland
  • Small molecules with drug-like properties producing neurotrophic and neuroprotective effects on human dopaminergic neurons
  • Disease modification and efficacy on both motor and non-motor symptoms
  • Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company
  • Additionally secured European grant of €2 million
  • Collaborative ecosystem

Mart Saarma
Scientific founder

Our latest news